CoChat

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Open access
Coffee, Erin M., Faber, Anthony C., Roper, Jatin, Sinnamon, Mark J., Goel, Gautam, Keung, Lily, Wang, Wei Vivian, Vecchione, Loredana, de Vriendt, Veerle, Weinstein, Barbara J., Bronson, Roderick T., Tejpar, Sabine, Xavier, Ramnik J., Engelman, Jeffrey A., Martin, Eric S., Hung, Kenneth E. · 2013 · Clinical Cancer Research
Cited by 79

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAFV600E CRC. Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR signaling in BRAFV600E CRC cell lines after BRAF inhibition and cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAFV600E CRC. Results: Western blot analysis revealed sustained PI3K/mTOR signaling upon BRAF inhibition. Our BRAFV600E GEMM presented with sessile serrated adenomas/polyps, as seen in humans. Combination treatment in vivo resulted in induction of apoptosis and tumor regression. Conclusions: We have established a novel GEMM to interrogate BRAFV600E CRC biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials. Clin Cancer Res; 19(10); 2688–98. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2556

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 79

Metadata

Authors
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B. J., Bronson, R. T., Tejpar, S., Xavier, R. J., Engelman, J. A., Martin, E. S., & Hung, K. E.
Venue
Clinical Cancer Research
Published
2013-05-12
Volume
19
Issue
10
Pages
2688-2698
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2149528253
Cited by
79
References
12
FWCI
7.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2556
The paper
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B. J., Bronson, R. T., Tejpar, S., Xavier, R. J., Engelman, J. A., Martin, E. S., & Hung, K. E. (2013). Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2556

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.